Nutriband CEO Gareth Sheridan Seeks Nomination in Upcoming Irish Presidential Election
Nutriband (NASDAQ:NTRB) announced that CEO Gareth Sheridan will temporarily step down for three months to pursue candidacy in the Irish Presidential election. Chairman and President Serguei Melnik will serve as interim CEO during September and October 2025.
The company recently received FDA meeting approval for AVERSA Fentanyl, their abuse-deterrent opioid patch. The product has projected peak annual US sales potential of $80-200 million and is protected by patents in 46 countries. The company remains on track for its planned NDA filing in 2026.
Nutriband (NASDAQ:NTRB) ha annunciato che l'amministratore delegato Gareth Sheridan si dimetterà temporaneamente per tre mesi per presentare la propria candidatura alle elezioni presidenziali in Irlanda. Il chairman e presidente Serguei Melnik assumerà il ruolo di amministratore delegato ad interim per settembre e ottobre 2025.
La società ha recentemente ottenuto l'approvazione della FDA per una riunione relativa a AVERSA Fentanyl, il loro cerotto oppioide con proprietà anti-abuso. Il prodotto ha un potenziale di vendite annue massime negli USA stimato tra 80 e 200 milioni di dollari ed è protetto da brevetti in 46 paesi. L'azienda resta in linea con la prevista presentazione della NDA nel 2026.
Nutriband (NASDAQ:NTRB) anunció que su consejero delegado Gareth Sheridan se apartará temporalmente durante tres meses para presentarse a la presidencia de Irlanda. El presidente del consejo y presidente Serguei Melnik ejercerá como CEO interino en septiembre y octubre de 2025.
La compañía obtuvo recientemente la aprobación de la FDA para una reunión sobre AVERSA Fentanyl, su parche opioide con tecnología antiabuso. El producto tiene un potencial máximo de ventas anuales en EE. UU. de 80-200 millones de dólares y está protegido por patentes en 46 países. La empresa mantiene el calendario previsto para presentar la NDA en 2026.
Nutriband (NASDAQ:NTRB)는 최고경영자(CEO) 개러스 셰리던이 아일랜드 대통령 선거 출마를 위해 3개월간 직무를 일시 중단한다고 발표했습니다. 이사회 의장 겸 사장 세르게이 멜니크가 2025년 9월과 10월 동안 임시 CEO를 맡습니다.
회사는 최근 남용 방지 기능을 갖춘 패치인 AVERSA Fentanyl과 관련해 FDA 미팅 승인을 받았습니다. 이 제품은 미국 내 연간 최대 매출 잠재력이 8천만~2억 달러로 추정되며 46개국에서 특허로 보호됩니다. 회사는 2026년 예정된 NDA 제출 일정이 계획대로 진행 중이라고 밝혔습니다.
Nutriband (NASDAQ:NTRB) a annoncé que son PDG Gareth Sheridan se mettra temporairement en congé pour trois mois afin de se présenter à l'élection présidentielle irlandaise. Le chairman et président Serguei Melnik assurera l'intérim en tant que PDG durant septembre et octobre 2025.
La société a récemment obtenu l'accord de la FDA pour une réunion concernant AVERSA Fentanyl, son patch opioïde doté d'un dispositif anti‑abus. Le produit présente un potentiel de ventes annuelles maximales aux États‑Unis de 80 à 200 millions de dollars et est protégé par des brevets dans 46 pays. L'entreprise reste dans les temps pour le dépôt prévu de la NDA en 2026.
Nutriband (NASDAQ:NTRB) gab bekannt, dass CEO Gareth Sheridan für drei Monate vorübergehend von seinem Amt zurücktreten wird, um als Kandidat bei der irischen Präsidentschaftswahl anzutreten. Vorstandsvorsitzender und President Serguei Melnik wird im September und Oktober 2025 als Interims-CEO fungieren.
Das Unternehmen erhielt kürzlich die Zustimmung der FDA zu einem Meeting für AVERSA Fentanyl, ihr missbrauchsresistentes Opioidpflaster. Das Produkt hat ein geschätztes maximales jährliches Umsatzpotenzial in den USA von 80–200 Millionen US-Dollar und ist durch Patente in 46 Ländern geschützt. Das Unternehmen liegt im Zeitplan für die geplante Einreichung der NDA im Jahr 2026.
- FDA granted meeting request for AVERSA Fentanyl abuse-deterrent patch
- AVERSA Fentanyl has potential peak US sales of $80-200 million annually
- Strong intellectual property protection with patents in 46 countries
- Experienced interim CEO with 20+ years of capital markets expertise
- Temporary leadership change as CEO steps aside for three months
- Potential disruption in executive continuity during critical pre-NDA period
Sheridan will temporarily step aside as CEO to enter the Irish Presidential Election.
Company Chairman and President, Serguei Melnik will take over as interim CEO over the course of the campaign and election period.
ORLANDO, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company CEO, Gareth Sheridan will be stepping aside from his role for three months to enter the Irish Presidential election. The Nomination Hearings followed by the Election will take place over the course of September and October.
During this period, Co-Founder and Chairman, Serguei Melnik will take over the responsibilities of CEO and guide the company through the final 2025 framework towards the target NDA filing in 2026. Mr. Melnik, a corporate strategy expert will continue to execute the Company’s strategic development and focus on shareholder value. Mr. Melnik has over 20 years experience in Capital markets.
"I have made the decision to temporarily step aside as CEO following the support and encouragement I have received asking me to put my name forward for the election for President of Ireland. Rest assured, Nutriband is in very safe hands. While most often we talk about AVERSA as our big opportunity, it is our tight knit team that is really our core asset. I look forward to watching Nutriband continue to hit its planned targets between now and December," said Mr. Sheridan.
The FDA recently granted Nutriband’s meeting request for AVERSA Fentanyl
AVERSA FENTANYL has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA FENTANYL has the potential to reach peak annual US sales of
The AVERSA™ abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
____________________________________________________
1 Health Advances Aversa Fentanyl market analysis report 2022
About AVERSA™ Abuse-Deterrent Transdermal Technology
Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
SOURCE: Nutriband Inc.
FAQ
Why is Nutriband (NTRB) CEO Gareth Sheridan stepping down?
Who will be Nutriband's interim CEO during Sheridan's absence?
What is the market potential for Nutriband's AVERSA Fentanyl patch?
What is the status of Nutriband's AVERSA Fentanyl development?
How many countries have granted patents for Nutriband's AVERSA technology?
